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The emergence and outbreak of a newly discovered
acute respiratory disease in Wuhan, China, has affected
greater than 40,000 people, and killed more than 1,000
as of Feb. 10, 2020. A new human coronavirus, SARS-
CoV-2, was quickly identified, and the associated dis-
ease is now referred to as coronavirus disease discov-
ered in 2019 (COVID-19) (https://globalbiodefense.
com/novel-coronavirus-covid-19-portal/).
According to what has been reported [1–3],
COVID-2019 seems to have similar clinical manifes-
tations to that of the severe acute respiratory syndrome
(SARS) caused by SARS-CoV. The SARS-CoV-2 gen-
ome sequence also has ∼80% identity with SARS-
CoV, but it is most similar to some bat beta-corona-
viruses, with the highest being >96% identity [4,5].
Currently, there are speculations, rumours and con-
spiracy theories that SARS-CoV-2 is of laboratory ori-
gin. Some people have alleged that the human SARS-
CoV-2 was leaked directly from a laboratory in
Wuhan where a bat CoV (RaTG13) was recently
reported, which shared ∼96% homology with the
SARS-CoV-2 [4]. However, as we know, the human
SARS-CoV and intermediate host palm civet SARS-
like CoV shared 99.8% homology, with a total of 202
single-nucleotide (nt) variations (SNVs) identified
across the genome [6]. Given that there are greater
than 1,100 nt differences between the human SARS-
CoV-2 and the bat RaTG13-CoV [4], which are distrib-
uted throughout the genome in a naturally occurring
pattern following the evolutionary characteristics typi-
cal of CoVs, it is highly unlikely that RaTG13 CoV is
the immediate source of SARS-CoV-2. The absence
of a logical targeted pattern in the new viral sequences
and a close relative in a wildlife species (bats) are the
most revealing signs that SARS-CoV-2 evolved by
natural evolution. A search for an intermediate animal
host between bats and humans is needed to identify
animal CoVs more closely related to human SARS-
CoV-2. There is speculation that pangolins might
carry CoVs closely related to SARS-CoV-2, but the
data to substantiate this is not yet published (https://
www.nature.com/articles/d41586-020-00364-2).
Another claim in Chinese social media points to a
Nature Medicine paper published in 2015 [7], which
reports the construction of a chimeric CoV with a
bat CoV S gene (SHC014) in the backbone of a SARS
CoV that has adapted to infect mice (MA15) and is
capable of infecting human cells [8]. However, this
claim lacks any scientific basis and must be discounted
because of significant divergence in the genetic
sequence of this construct with the new SARS-CoV-2
(>5,000 nucleotides).
The mouse-adapted SARS virus (MA15) [9] was
generated by serial passage of an infectious wildtype
SARS CoV clone in the respiratory tract of BALB/c
mice. After 15 passages in mice, the SARS-CoV gained
elevated replication and lung pathogenesis in aged mice
(hence M15), due to six coding genetic mutations
associated with mouse adaptation. It is likely that
MA15 is highly attenuated to replicate in human cells
or patients due to the mouse adaptation.
It was proposed that the S gene from bat-derived
CoV, unlike that from human patients- or civets-
derived viruses, was unable to use human ACE2 as a
receptor for entry into human cells [10,11]. Civets
were proposed to be an intermediate host of the bat-
CoVs, capable of spreading SARS CoV to humans
[6,12]. However, in 2013 several novel bat corona-
viruses were isolated from Chinese horseshoe bats
and the bat SARS-like or SL-CoV-WIV1 was able to
use ACE2 from humans, civets and Chinese horseshoe
bats for entry [8]. Combined with evolutionary
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evidence that the bat ACE2 gene has been positively
selected at the same contact sites as the human ACE2
gene for interacting with SARS CoV [13], it was pro-
posed that an intermediate host may not be necessary
and that some bat SL-CoVs may be able to directly
infect human hosts. To directly address this possibility,
the exact S gene from bat coronavirus SL-SHC014 was
synthesized and used to generate a chimeric virus in the
mouse adaptedMA15 SARS-CoV backbone. The resul-
tant SL-SHC014-MA15 virus could indeed efficiently
use human ACE2 and replicate in primary human
airway cells to similar titres as epidemic strains of
SARS-CoV. While SL-SHC014-MA15 can replicate
efficiently in young and aged mouse lungs, infection
was attenuated, and less virus antigen was present in
the airway epithelium as compared to SARS MA15,
which causes lethal outcomes in aged mice [7].
Due to the elevated pathogenic activity of the
SHC014-MA15 chimeric virus relative to MA15 chi-
meric virus with the original human SARS S gene in
mice, such experiments with SL-SHC014-MA15 chi-
meric virus were later restricted as gain of function
(GOF) studies under the US government-mandated
pause policy (https://www.nih.gov/about-nih/who-we-
are/nih-director/statements/nih-lifts-funding-pause-
gain-function-research). The current COVID-2019
epidemic has restarted the debate over the risks of con-
structing such viruses that could have pandemic poten-
tial, irrespective of the finding that these bat CoVs
already exist in nature. Regardless, upon careful phylo-
genetic analyses by multiple international groups
[5,14], the SARS-CoV-2 is undoubtedly distinct from
SL-SHC014-MA15, with >6,000 nucleotide differences
across the whole genome. Therefore, once again there
is no credible evidence to support the claim that the
SARS-CoV-2 is derived from the chimeric SL-
SHC014-MA15 virus.
There are also rumours that the SARS-CoV-2 was
artificially, or intentionally, made by humans in the
lab, and this is highlighted in one manuscript sub-
mitted to BioRxiv (a manuscript sharing site prior to
any peer review), claiming that SARS-CoV-2 has
HIV sequence in it and was thus likely generated in
the laboratory. In a rebuttal paper led by an HIV-1 vir-
ologist Dr. Feng Gao, they used careful bioinformatics
analyses to demonstrate that the original claim of mul-
tiple HIV insertions into the SARS-CoV-2 is not HIV-1
specific but random [15]. Because of the many con-
cerns raised by the international community, the
authors who made the initial claim have already with-
drawn this report.
Evolution is stepwise and accrues mutations gradu-
ally over time, whereas synthetic constructs would typi-
cally use a known backbone and introduce logical or
targeted changes instead of the randomly occurring
mutations that are present in naturally isolated viruses
such as bat CoV RaTG13. In our view, there is
currently no credible evidence to support the claim
that SARS-CoV-2 originated from a laboratory-engin-
eered CoV. It is more likely that SARS-CoV-2 is a
recombinant CoV generated in nature between a bat
CoV and another coronavirus in an intermediate ani-
mal host. More studies are needed to explore this possi-
bility and resolve the natural origin of SARS-CoV-2.
We should emphasize that, although SARS-CoV-2
shows no evidence of laboratory origin, viruses with
such great public health threats must be handled prop-
erly in the laboratory and also properly regulated by the
scientific community and governments.
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